文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌高剂量率近距离放疗后急性尿潴留风险估计:基于临床的递归分割分析

Estimating acute urinary retention risk post prostate high dose-rate (HDR) brachytherapy: A clinical-based recursive partitioning analysis.
PubMed 文献 · Radiother Oncol · 2020-09-20

该回顾性研究纳入425例接受15 Gy高剂量率近距离放疗 boost 后联合外照射的前列腺癌患者,评估术后30天内需导尿的尿潴留和血尿。多因素分析显示前列腺体积、既往使用α受体阻滞剂和ADT使用是尿潴留的显著预测因素,递归分割分析识别出尿潴留率从2%到50%不等的亚组。

要点

  • 15 Gy HDR-BT后30天内急性尿潴留需导尿率为6.3%,血尿需导尿率为3%。
  • 前列腺体积、既往α受体阻滞剂使用和ADT使用是多因素分析中尿潴留的显著预测因素。
  • 递归分割分析分类树可识别尿潴留风险从2%到50%不等的患者亚组。

核心结论

  • HDR近距离放疗后急性泌尿并发症总体发生率低,但个体尿潴留风险随风险因素数量增加而升高。
  • 本研究所提出的分类风险树可用于更个体化的尿潴留风险评估。

研究设计与样本

  • 回顾性评估425例接受15 Gy HDR-BT boost后联合EBRT的前列腺癌患者。
  • 评估术后30天内需导尿的尿潴留和血尿,采用单因素和多因素logistic回归分析预测因素,并利用递归分割分析(RPA)构建尿潴留风险分类树。

主要发现

  • 单因素分析中,穿刺针数、前列腺体积、既往使用ADT、α受体阻滞剂或5α还原酶抑制剂与尿潴留统计学相关。
  • 多因素分析中,前列腺体积、既往使用α受体阻滞剂和ADT使用保持显著。
  • RPA识别出尿潴留率从2%到50%不等的患者亚组,取决于一个或多个风险因素的存在。

关键数值与推荐

  • RPA分类树识别的亚组尿潴留率范围为2%至50%。

临床怎么用

  • 可利用本研究的分类风险树,根据前列腺体积、既往α受体阻滞剂使用和ADT使用等因素进行患者个体化尿潴留风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine factors associated with need for post-procedural catheterization in prostate cancer patients treated with 15 Gy high dose-rate brachytherapy boost (HDR-BT). MATERIAL AND METHODS: Patients treated with 15 Gy HDR-BT followed by EBRT were retrospectively evaluated for development of urinary retention and hematuria requiring catheterization in the first 30 days post procedure. Clinical characteristics and treatment details were obtained and used as independent variables under study. Univariable and multivariable logistic regression analysis were used to determine predictors of post brachytherapy complications and a classification tree for risk of urinary retention was created using recursive partitioning analysis (RPA). RESULTS: A total of 425 patients treated with 15 Gy HDR-BT were included in this analysis. 27 patients (6.3%) required catheter placement due to acute urinary retention and thirteen other patients (3%) developed hematuria requiring urinary catheter insertion ± continuous bladder irrigation. Number of needles, prostate volume and prior use of ADT, alpha-blockers or 5α-reductase inhibitors were statistically associated with urinary retention in the univariable logistic regression analysis. In multivariable analysis, prostate volume, previous use of alpha-blocker, and use of ADT remained significant. In the RPA, populations were identified in which the rate of urinary retention ranged from 2% to 50% depending on presence of one or more of these risk factors. CONCLUSION: The overall rate of acute urinary complications post HDR brachytherapy is low, but the individual risk of urinary retention can increase depending on the number of risk factors present. A more patient-directed retention risk estimation can be performed by using the classification risk tree presented here.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Mendez LC, Loblaw A, Chung HT, et al. Estimating acute urinary retention risk post prostate high dose-rate (HDR) brachytherapy: A clinical-based recursive partitioning analysis. Radiother Oncol. 2020. PMID: 32966843. doi:10.1016/j.radonc.2020.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。